Boston — Biocytogen said its Boston research facility has received full accreditation from AAALAC International, a global organization that promotes standards for laboratory animal care and use.
The company said the accreditation reflects its commitment to animal welfare, scientific integrity and operational excellence across its preclinical research and drug discovery work.
Biocytogen’s Boston facility supports the company’s drug discovery and translational research operations, including in vivo studies for antibody therapeutics, multispecific antibodies, antibody-drug conjugates, cell therapies and other biologics programs for pharmaceutical and biotechnology partners.
The company said its proprietary BioMice platform includes a broad collection of genetically engineered disease models across oncology, immunology and autoimmune diseases, metabolic disorders, neuroscience, ophthalmology and other therapeutic areas.
Biocytogen said those capabilities, combined with its RenMice fully human antibody discovery platforms and AI-enabled antibody discovery technologies, are designed to help partners accelerate target validation, therapeutic discovery and preclinical development.
“Receiving full AAALAC accreditation represents an important milestone for our Boston research operations and further demonstrates our commitment to scientific excellence, animal welfare, and responsible research practices,” said Madeline Lee, Chief Operating Officer of Biocytogen. “As we continue expanding our global partnerships, this accreditation provides additional assurance that our research programs are conducted under the highest standards of animal care, quality, and scientific rigor. Together with our industry-leading disease model portfolio and antibody discovery platforms, we remain committed to helping our partners accelerate the development of innovative medicines for patients worldwide.”
AAALAC International accreditation is widely regarded as a leading standard for laboratory animal care and use programs. The accreditation recognizes institutions that voluntarily demonstrate standards beyond regulatory requirements and maintain a culture of continuous improvement in animal welfare, ethical research practices and scientific quality.
Biocytogen said the accreditation strengthens its ability to support global pharmaceutical and biotechnology companies with translational research, in vivo pharmacology and therapeutic discovery services. The company said maintaining high standards for animal welfare and scientific rigor helps partners generate reliable preclinical data, reduce development risk and advance next-generation medicines across multiple therapeutic areas.
